A differentiated way to support neuropsychiatry assets across the lifecycle

Osmind actively supports sponsors ranging from top 5 pharma to clinical stage biotechs to neurotechnology companies.

Our projects have included retrospective RWD analyses, fit-for-purpose registries, prospective data capture, data-driven trials recruitment, market research, and commercial activation (e.g. HCP education, patient identification).

A man in a red tie standing next to a woman in a blue dress.

Making an impact on psychiatry

"Osmind is doing important, much-needed work. I truly believe that we are at an inflection point in our ability to markedly improve outcomes for our patients – both from an improved understanding of novel therapeutics, and our ability to move towards precision medicine."

Husseini K. Manji, M.D., F.R.C.P.C.
Former Global Head of Neuroscience at Janssen Research & Development

“Our collaboration with Osmind offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.”

Nitin Gogtay, MD
Chief of Research and Deputy Medical Director, American Psychiatric Association

"Working with Osmind was the first time my RWE group used EHR data. We had looked in the past but couldn't find any other EHR data with deep outcomes data. Our project with Osmind was very successful, with a combination of strong RWD and impressive analytic outputs all delivered ahead of schedule. The results are making a big impact internally and externally with payers and HCPs."

Group Director
Top 5 Pharma

“Osmind’s approach to unlocking next-generation treatments by leveraging real-world evidence and their digital infrastructure has the potential to meaningfully impact our ability to bring new treatments to patients in dire need. They’ve made incredible progress already.”

Brent Saunders
CEO of Bausch + Lomb; past Chairman, President, and CEO at Allergan

Backed by industry leaders

A close up of a person wearing a suit and tie.

Husseini Manji, MD

Former Global Head of Neuroscience, J&J

Rob Berman, MD

Co-founder and former Chief Medical Officer, Biohaven Pharmaceuticals

A man in a lab coat and tie.

Jeff Leiden, MD, PhD

Executive Chairman, former President and CEO, Vertex Pharmaceuticals

A man in a suit and tie smiling at the camera.

Brent Saunders

CEO, Bausch & Lomb; Former CEO & Chairman, Allergan

Connecting the point-of-care with life sciences innovation

Our software is the
system of record

Our fully-integrated software platform includes an EHR, patient app, practice management system, clinician community, and advanced analytics system

Depth and quality of real-world data

High quality clinical and outcomes data at scale. Structured for research from the point of data generation, e.g. from our library of 40+ outcomes measures

Direct relationship
with clinics

Network of engaged, research-forward clinicians using our software and in our proprietary clinician community

Direct relationship
with patients

Network of engaged patients actively using our software

Accelerate your programs across the development lifecycle

Trusted by leading companies. Below are examples from recent
projects we have conducted.

Translational research

Example: We used RWD to develop novel subtypes of psychiatric conditions for more precise therapeutic targeting

Clinical development

Example: We used RWD to help design clinical trials and recruit patients for studies

Medical affairs, HEOR

Example: We assessed the real-world effectiveness and treatment patterns of novel psychiatric therapies and produced high-impact publications geared towards HCPs and payers


Example: We conducted market research studies to understand clinician perspectives, educated clinicians about new treatments, and helped them adjust their workflows accordingly (e.g. with the automation of REMS)

What we do

  • RWE, retrospective analyses of RWD
  • Fit-for-purpose registries, prospective data capture, pragmatic trials
  • Data-driven trials recruitment
  • Market research (qualitative, quantitative, linkage with RWD)
  • Commercial activation, HCP engagement and education, patient identification
A group of people sitting around a wooden table.

Featured news & research

Featured Update
Jul 10, 2024

Osmind Welcomes Former Global Head of Neuroscience at J&J, Husseini Manji, MD, as a Strategic Advisor

Featured Research
Jun 14, 2024

Successful dTMS in rTMS, ECT, and Ketamine Refractory Depression: A Case Series

Aslam, Handoo, MacMillan, Muir (2024). Clinical TMS Society Annual Meeting.

Featured Research
Jun 14, 2024

Utilizing nVNS Treatment Effectively After Non-Response to Accelerated H7 and H1 Treatment in Highly Refractory Depression: A Case Report

Aslam, MacMillan, Muir (2024) Clinical TMS Society Annual Meeting.

Featured Research
Jun 8, 2024

Peril and Promise: Teens, Tech, and America’s Mental Health Crisis

Belfort, MacMillan, Weigle (2024). Child and Adolescent Psychiatric Clinics of North America.

Featured Research
May 28, 2024

Comparative Effectiveness of Ketamine Intravenous Therapy and Intranasal Esketamine for Depression in Real-world Settings

McInnes and Kane (2024). American Society of Clinical Psychopharmacology Annual Meeting.

Featured Research
May 28, 2024

A retrospective study of real-world outcomes for esketamine nasal spray among patients with treatment resistant depression

McInnes, Joshi, Kane, et al. (2024). American Society of Clinical Psychopharmacology Annual Meeting.

Featured Update
July 10, 2024

Osmind Welcomes Former Global Head of Neuroscience at J&J, Husseini Manji, MD, as a Strategic Advisor

Featured Update
May 2, 2024

Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research

Featured Update
March 7, 2024

Osmind Announces 2024 Community Advisory Board: Leading Mental Health Clinicians

Featured Update
May 11, 2023

Osmind Announces 2023 Community Advisory Board: Leading Mental Health Clinicians

Featured Research
May 4, 2024

Measurement Based Care Learning Lab

MacMillan (2024). American Psychiatric Association Annual Meeting.

Featured Research
May 4, 2024

Psychiatric Treatments that have FDA’s Breakthrough Therapy Status

MacMillan (2024). American Psychiatric Association Annual Meeting.

Featured Research
Mar 15, 2024

A phase 2 trial with CLE-100 oral esketamine for patients with MDD and inadequate response to antidepressant during COVID-19 pandemic

Hagai et al. (2024). Oxford Ketamine Conference.

Featured Research
Feb 13, 2024

Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines

McInnes and Marton (2024). Current Psychiatry Research and Reviews.

Featured Research
Feb 11, 2024

Embracing pragmatism for ketamine insurance coverage: Leveraging real-world evidence

McInnes, Marton, Qian (2024). Journal of Affective Disorders.

Featured Research
Dec 8, 2023

Machine Learning (ML) Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy (KIT)

Kane, Worley, McInnes (2023). American Society of Ketamine Physicians, Psychotherapists & Practitioners Annual Meeting.

Learn more about Osmind’s research and real-world evidence
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

If you, or someone you know, is in crisis or needs immediate assistance, please call 911 immediately. To talk to someone now, please call the National Suicide Prevention Lifeline at 1-800-273-8255.

Osmind Inc. © 2024 All Rights Reserved.